15-valent pneumococcal conjugate vaccine (PCV15)

Phase 2

PFIZER (PFE)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

PFEPhase 2$160.0B

15-valent pneumococcal conjugate vaccine (PCV15) Phase 2 Est. Readout

15-valent pneumococcal conjugate vaccine (PCV15)• Pneumococcal Disease605

Q2 2027~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Pneumococcal Disease

View Full Landscape

Drug Information

Target Indication

Pneumococcal Disease

Clinical Trial

NCT06524414

Last updated: 3/11/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Insulin LisproPhase 3

Diabetes Mellitus

Cyclosporine APhase 3

Renal Transplantation

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

MeropenemPhase 3

Complicated Intra-abdominal Infections

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts